Mounjaro KwikPen Tirzepatide 10mg/0.6ml is an FDA-approved dual GIP/GLP-1 receptor agonist injection designed to improve blood sugar control in adults with type 2 diabetes. Available as a convenient four-dose pre-filled pen, this once-weekly subcutaneous injection by Eli Lilly activates two key hormones to support insulin production, reduce appetite, and promote meaningful weight reduction when used alongside diet and exercise in the UAE.

How Mounjaro Tirzepatide 10mg Works

Mounjaro contains tirzepatide, the first dual GIP and GLP-1 receptor agonist approved for type 2 diabetes management. Unlike single-action GLP-1 medications, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. This dual mechanism helps your body produce more insulin when blood sugar is elevated, reduces glucose output from the liver, and slows gastric emptying to promote satiety. Clinical trials demonstrated that the 10mg dose reduced HbA1c by up to 2.30% and achieved an average weight loss of 19.5% over 72 weeks.

Active Ingredient

• Tirzepatide 10mg per 0.6ml dose - dual GIP/GLP-1 receptor agonist

• Inactive ingredients: sodium chloride, sodium phosphate dibasic heptahydrate, water for injection

• Additional excipients in KwikPen: benzyl alcohol, glycerin, phenol

• Solution appearance: clear, colorless to slightly yellow

• Each KwikPen contains 40mg tirzepatide in 2.4ml, delivering four weekly 10mg doses

Dosage and Administration

1. Inject 0.6ml subcutaneously once weekly, at any time of day, with or without meals

2. Rotate injection sites between the abdomen, front of thigh, or upper arm (with caregiver assistance)

3. Maintain at least 3 days between doses if changing your injection day

4. Dispose of the KwikPen after all four doses are used

5. Store refrigerated at 2-8 degrees Celsius; may be kept at room temperature for up to 21 days

Your doctor will determine the appropriate dose escalation schedule. The 10mg dose is typically reached after gradual increases from the 2.5mg starting dose, with adjustments made no more frequently than every 4 weeks.

Important Safety Information

Mounjaro is a prescription-only medication in the UAE. Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects include nausea, diarrhea, decreased appetite, vomiting, and constipation - these typically diminish as your body adjusts. Risk of hypoglycemia increases when used with sulfonylureas or insulin. Mounjaro may reduce the effectiveness of oral contraceptives. Consult your healthcare provider before starting treatment, especially if you are pregnant, breastfeeding, or have a history of pancreatitis, kidney disease, or diabetic retinopathy.